Inlyta — Revenues:
Pfizer Inlyta — Revenues: decreased by 8.9% to $214.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.3%, from $219.00M to $214.00M. Over 4 years (FY 2021 to FY 2025), Inlyta — Revenues: shows relatively stable performance with a -2.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption, successful commercial execution, or expanded clinical indications, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net sales generated from the specific oncology product line within the company's pharma...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or therapeutic assets reported by other large-cap pharmaceutical companies, often evaluated against the product's patent protection status and market share within its specific therapeutic class.
pfe_segment_inlyta_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $257.00M | $256.00M | $260.00M | $234.00M | $274.00M | $252.00M | $243.00M | $259.00M | $262.00M | $252.00M | $263.00M | $237.00M | $252.00M | $247.00M | $242.00M | $219.00M | $243.00M | $226.00M | $235.00M | $214.00M |
| QoQ Change | — | -0.4% | +1.6% | -10.0% | +17.1% | -8.0% | -3.6% | +6.6% | +1.2% | -3.8% | +4.4% | -9.9% | +6.3% | -2.0% | -2.0% | -9.5% | +11.0% | -7.0% | +4.0% | -8.9% |
| YoY Change | — | — | — | — | +6.6% | -1.6% | -6.5% | +10.7% | -4.4% | +0.0% | +8.2% | -8.5% | -3.8% | -2.0% | -8.0% | -7.6% | -3.6% | -8.5% | -2.9% | -2.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's inlyta — revenues:?
- Pfizer (PFE) reported inlyta — revenues: of $214.00M in Q1 2026.
- How has Pfizer's inlyta — revenues: changed year-over-year?
- Pfizer's inlyta — revenues: decreased by 2.3% year-over-year, from $219.00M to $214.00M.
- What is the long-term trend for Pfizer's inlyta — revenues:?
- Over 4 years (2021 to 2025), Pfizer's inlyta — revenues: has grown at a -2.0% compound annual growth rate (CAGR), from $1.00B to $923.00M.
- What does inlyta — revenues: mean?
- The total revenue generated by the sales of a specific oncology drug product.